Study: Cambridge-based Genzyme Corp.'s Thymoglobulin for patients undergoing kidney transplants is more effective than Novartis AG's Simulect in reducing the risk of organ rejection and the severity when it occurs, according to a company-sponsored study. (Full article: 311 words)
This article is available in our archives:
Globe Subscribers
FREE for subscribers
Subscribers to the Boston Globe get unlimited access to our archives.
Not a subscriber?
Non-Subscribers
Purchase an electronic copy of the full article. Learn More
- $4.95 1 article
- $9.95 4 articles
- $25.95 Monthly
